Ginkgo Bioworks Holdings (DNA) Liabilities and Shareholders Equity (2020 - 2025)

Ginkgo Bioworks Holdings filings provide 6 years of Liabilities and Shareholders Equity readings, the most recent being $1.1 billion for Q4 2025.

  • On a quarterly basis, Liabilities and Shareholders Equity fell 18.71% to $1.1 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $4.8 billion, a 20.31% decrease, with the full-year FY2025 number at $1.1 billion, down 18.71% from a year prior.
  • Liabilities and Shareholders Equity hit $1.1 billion in Q4 2025 for Ginkgo Bioworks Holdings, down from $1.2 billion in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $2.5 billion in Q4 2022 to a low of $1.1 billion in Q4 2025.
  • Median Liabilities and Shareholders Equity over the past 5 years was $1.7 billion (2021), compared with a mean of $1.8 billion.
  • Biggest five-year swings in Liabilities and Shareholders Equity: soared 206.74% in 2021 and later plummeted 34.56% in 2024.
  • Ginkgo Bioworks Holdings' Liabilities and Shareholders Equity stood at $2.1 billion in 2021, then increased by 22.61% to $2.5 billion in 2022, then plummeted by 34.42% to $1.7 billion in 2023, then dropped by 17.29% to $1.4 billion in 2024, then dropped by 18.71% to $1.1 billion in 2025.
  • The last three reported values for Liabilities and Shareholders Equity were $1.1 billion (Q4 2025), $1.2 billion (Q3 2025), and $1.2 billion (Q2 2025) per Business Quant data.